Precision Medicine Driven by the SPECTRA Network Biology Platform in Neurodegenerative Disorders

Time: 10:00 am
day: Day Two


  • Learning about SPECTRA: A propriety integrative multi-omics network biology platform bringing first-in-class precision medicines to patients by identifying novel targets, drug repurposing candidates, drug response predictions, drug downstream molecular effects, biomarker discovery and patient stratification.
  • Through SPECTRA analyses, we help inform treatment selection to guide patients to therapies most likely be effective for them, with the overall goal of improving drug responses early in the disease timeline, preventing the progression of disease.
  • Scipher’s therapeutics pipeline has demonstrated the ability to identify promising drug targets as evidenced by successful experimental preclinical validation in disease models, an approach now being applied to neurodegenerative diseases.